GRI insider filings
GRI Bio, Inc. — 37 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-13. Screen GRI transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 4 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Baker David Charles — Director | 1 | — | — | 1 |
| Rongen Roelof — Director | 1 | — | — | 1 |
| SIMPSON CAMILLA V — Director | 1 | — | — | 1 |
| Szekeres David Leslie — Director | 1 | — | — | 1 |
Recent insider filings — GRI Bio, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-13 | 4 | Szekeres David Leslie — Director | Grant/award (A): 6,558 (derivative) @ $0 | EDGAR |
| 2026-11-13 | 4 | Rongen Roelof — Director | Grant/award (A): 3,935 (derivative) @ $0 | EDGAR |
| 2026-11-13 | 4 | SIMPSON CAMILLA V — Director | Grant/award (A): 3,935 (derivative) @ $0 | EDGAR |
| 2026-11-13 | 4 | Baker David Charles — Director | Grant/award (A): 3,935 (derivative) @ $0 | EDGAR |
| 2025-09-22 | 4 | Chaturvedi Vipin — Chief Scientific Officer | Grant/award (A): 43,222 (derivative) @ $0 | EDGAR |
| 2025-09-22 | 4 | Hertz Walter Marc — Chief Executive Officer, Director | Grant/award (A): 103,067 (derivative) @ $0 | EDGAR |
| 2025-09-22 | 4 | Baker David Charles — Director | Grant/award (A): 23,605 (derivative) @ $0 | EDGAR |
| 2025-09-22 | 4 | SIMPSON CAMILLA V — Director | Grant/award (A): 23,605 (derivative) @ $0 | EDGAR |
| 2025-09-22 | 4 | Rongen Roelof — Director | Grant/award (A): 23,605 (derivative) @ $0 | EDGAR |
| 2025-09-22 | 4 | Szekeres David Leslie — Director | Grant/award (A): 39,897 (derivative) @ $0 | EDGAR |
| 2025-09-22 | 4 | Kelly Leanne — Chief Financial Officer | Grant/award (A): 43,222 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | Hertz Walter Marc — Chief Executive Officer, Director | Grant/award (A): 26,688 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | Baker David Charles — Director | Grant/award (A): 5,994 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | Chaturvedi Vipin — Chief Scientific Officer | Grant/award (A): 11,854 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | SIMPSON CAMILLA V — Director | Grant/award (A): 5,994 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | Rongen Roelof — Director | Grant/award (A): 5,994 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | Szekeres David Leslie — Director | Grant/award (A): 10,276 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | Kelly Leanne — Chief Financial Officer | Grant/award (A): 11,854 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Baker David Charles — Director | Grant/award (A): 4,527 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | SIMPSON CAMILLA V — Director | Grant/award (A): 4,527 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Rongen Roelof — Director | Grant/award (A): 4,527 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Szekeres David Leslie — Director | Grant/award (A): 7,545 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | Chaturvedi Vipin — Chief Scientific Officer | Grant/award (A): 43,319 (derivative) @ $0.69 | EDGAR |
| 2025-01-24 | 4 | Hertz Walter Marc — Chief Executive Officer, Director | Grant/award (A): 129,730 (derivative) @ $0.69 | EDGAR |
| 2025-01-24 | 4 | Baker David Charles — Director | Grant/award (A): 30,297 (derivative) @ $0.69 | EDGAR |
| 2025-01-24 | 4 | SIMPSON CAMILLA V — Director | Grant/award (A): 30,297 (derivative) @ $0.69 | EDGAR |
| 2025-01-24 | 4 | Rongen Roelof — Director | Grant/award (A): 30,297 (derivative) @ $0.69 | EDGAR |
| 2025-01-24 | 4 | Szekeres David Leslie — Director | Grant/award (A): 51,937 (derivative) @ $0.69 | EDGAR |
| 2025-01-24 | 4 | Kelly Leanne — Chief Financial Officer | Grant/award (A): 43,319 (derivative) @ $0.69 | EDGAR |
| 2023-09-26 | 4 | Kelly Leanne — Chief Financial Officer | Grant/award (A): 83,333 (derivative) @ $1.52 | EDGAR |
| 2023-08-14 | 4 | Baker David Charles — Director | Grant/award (A): 34,483 (derivative) @ $2.90 | EDGAR |
| 2023-08-14 | 4 | SIMPSON CAMILLA V — Director | Grant/award (A): 34,483 (derivative) @ $2.90 | EDGAR |
| 2023-08-14 | 4 | Rongen Roelof — Director | Grant/award (A): 34,483 (derivative) @ $2.90 | EDGAR |
| 2023-08-14 | 4 | Szekeres David Leslie — Director | Grant/award (A): 34,483 (derivative) @ $2.90 | EDGAR |
| 2023-04-24 | 4 | Hertz Walter Marc — Chief Executive Officer, Director, 10% owner | Grant/award (A): 385,510 | EDGAR |
| 2023-04-24 | 4 | Chaturvedi Vipin — Chief Scientific Officer | Grant/award (A): 172,189 | EDGAR |
| 2023-04-24 | 4 | Agro Albert — Chief Medical Officer | Grant/award (A): 172,189 | EDGAR |
Recent 8-K events — GRI Bio, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-28 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-21 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-16 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-01-15 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GRI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs